No­var­tis signs land­mark li­cens­ing deal to ex­pand ac­cess to patent­ed can­cer drug

The Med­i­cines Patent Pool on Thurs­day un­veiled a new vol­un­tary li­cens­ing agree­ment with No­var­tis to in­crease ac­cess to its patent­ed, sec­ond-line chron­ic myeloid leukemia drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER